Merck KGaA Completes Acquisition Of SpringWorks Therapeutics
3 Articles
3 Articles
With the intention of closing a therapeutic gap in rare tumours, the Merck Group is buying Springworks Therapeutics, a US company that aims to boost its sales.
Largest pharmaceutical business in 20 years: The Darmstadt-based group Merck buys Springworks for three billion euros – and relies on new therapies against rare tumors.
Merck KGaA Completes Acquisition Of SpringWorks Therapeutics
SpringWorks immediately adds revenue and accelerates mid- to long-term growth for Merck KGaA, Darmstadt, Germany’s Healthcare business sector. Acquisition marks the formation of a rare tumor business for Merck KGaA, Darmstadt, Germany including SpringWorks’ portfolio and pimicotinib. SpringWorks’ rare tumor portfolio includes Ogsiveo, a first-in-disease systemic therapy for adults with desmoid tumors and Gomekli a first and only approved therapy…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium